These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 4146693)

  • 1. Preparation of 9-tetrahydrocannabinol for intravenous injection.
    Olsen JL; Makhani M; Davis KH; Wall ME
    J Pharm Pharmacol; 1973 Apr; 25(4):344. PubMed ID: 4146693
    [No Abstract]   [Full Text] [Related]  

  • 2. An intravenous formulation of 9-tetrahydrocannabinol using a non-ionic surfactant.
    Cradock JC; Davignon JP; Litterst CL; Guarino AM
    J Pharm Pharmacol; 1973 Apr; 25(4):345. PubMed ID: 4146694
    [No Abstract]   [Full Text] [Related]  

  • 3. Intravenous injection in man of 9 -tetrahydrocannabinol and 11-OH- 9 -tetrahydrocannabinol.
    Perez-Reyes M; Timmons MC; Lipton MA; Davis KH; Wall ME
    Science; 1972 Aug; 177(4049):633-5. PubMed ID: 4558903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison among four vehicles and four routes for administering delta9-tetrahydrocannabinol.
    Sofia RD; Kubena RK; Barry H
    J Pharm Sci; 1974 Jun; 63(6):939-41. PubMed ID: 4851104
    [No Abstract]   [Full Text] [Related]  

  • 5. Vehicle and route of administration as parameters affecting operant behavioral effects of 9 -tetrahydrocannabinol.
    Borgen LA; Davis WM
    J Pharm Sci; 1973 Mar; 62(3):479-80. PubMed ID: 4691712
    [No Abstract]   [Full Text] [Related]  

  • 6. Delta-8- and delta-9-tetrahydrocannabinol comparison in man by oral and intravenous administration.
    Hollister LE; Gillespie HK
    Clin Pharmacol Ther; 1973; 14(3):353-7. PubMed ID: 4698563
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of four vehicles for intraperitoneal administration of -tetrahydrocannabinol.
    Sofia RD; Kubena RK; Barry H
    J Pharm Pharmacol; 1971 Nov; 23(11):889-91. PubMed ID: 4400204
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term use of marihuana and the development of tolerance or sensitivity to delta9 tetrahydrocannabinol.
    Perez-Reyes M; Timmons MC; Wall ME
    Arch Gen Psychiatry; 1974 Jul; 31(1):89-91. PubMed ID: 4835989
    [No Abstract]   [Full Text] [Related]  

  • 9. A comparison of the pharmacological activity in man of intravenously administered delta9-tetrahydrocannabinol, cannabinol, and cannabidiol.
    Perez-Reyes M; Timmons MC; Davis KH; Wall EM
    Experientia; 1973 Nov; 29(11):1368-9. PubMed ID: 4761242
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of delta9-tetrahydrocannabinol on social behaviour in mice: comparison between two vehicles.
    Dorr M; Steinberg H
    Psychopharmacology (Berl); 1976 May; 47(1):87-91. PubMed ID: 986665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral and parenteral formulations of marijuana constituents.
    Rosenkrantz H; Thompson GR; Braude MC
    J Pharm Sci; 1972 Jul; 61(7):1106-12. PubMed ID: 4625586
    [No Abstract]   [Full Text] [Related]  

  • 12. An inhalation aerosol of delta9-tetrahydrocannabinol.
    Olsen JL; Lodge JW; Shapiro BJ; Tashkin DP
    J Pharm Pharmacol; 1976 Jan; 28(1):86. PubMed ID: 6665
    [No Abstract]   [Full Text] [Related]  

  • 13. Central implantation of cannabinoids: induction of epileptiform discharges.
    Segal M
    Eur J Pharmacol; 1974 Jun; 27(1):40-5. PubMed ID: 4850929
    [No Abstract]   [Full Text] [Related]  

  • 14. Distribution studies of (14C)delta-9-tetrahydrocannabinol in mice: effect of vehicle, route of administration, and duration of treatment.
    Mantilla-Plata B; Harbison RD
    Toxicol Appl Pharmacol; 1975 Nov; 34(2):292-300. PubMed ID: 1209626
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects on humans of 9 -tetrahydrocannabinol administered by smoking.
    Galanter M; Wyatt RJ; Lemberger L; Weingartner H; Vaughan TB; Roth WT
    Science; 1972 May; 176(4037):934-6. PubMed ID: 4555981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticonvulsant activity of delta-8- and delta-9-tetrahydrocannabinol in rats.
    McCaughran JA; Corcoran ME; Wada JA
    Pharmacol Biochem Behav; 1974; 2(2):227-33. PubMed ID: 4829599
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of cannabis extract, 9 -tetrahydrocannabinol and lysergic acid diethylamide on rat liver enzymes.
    Poddar MK; Ghosh JJ
    Biochem Pharmacol; 1972 Dec; 21(24):3301-3. PubMed ID: 4405370
    [No Abstract]   [Full Text] [Related]  

  • 18. Metabolism and distribution of cannabinoids in rats after different methods of administration.
    Leighty EG
    Biochem Pharmacol; 1973 Jul; 22(13):1613-21. PubMed ID: 4729809
    [No Abstract]   [Full Text] [Related]  

  • 19. Cannabidiol interferes with the effects of delta 9 - tetrahydrocannabinol in man.
    Karniol IG; Shirakawa I; Kasinski N; Pfeferman A; Carlini EA
    Eur J Pharmacol; 1974 Sep; 28(1):172-7. PubMed ID: 4609777
    [No Abstract]   [Full Text] [Related]  

  • 20. Acute pulmonary physiologic effects of smoked marijuana and oral (Delta)9 -tetrahydrocannabinol in healthy young men.
    Tashkin DP; Shapiro BJ; Frank IM
    N Engl J Med; 1973 Aug; 289(7):336-41. PubMed ID: 4718513
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.